Review Article
Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis
Table 2
Summary of the most important therapeutical trials targeting IL-17 in RA.
| Name | Molecular target | Phase | Status | Patients | Weeks | Efficacy | Reference |
| Secukinumab | IL-17A | I | Completed | 52 | 6 | Supported | [70] | II | Completed | 237 | 16 | Supported | [71] | II | Completed | 174 | 52 | Supported | [72] | III | Ongoing | n/a | n/a | n/a | NCT01377012 | III | Ongoing | n/a | n/a | n/a | NCT01350804 |
| Ixekizumab | IL-17A | I | Completed | 97 | 10 | Supported | [73] | II | Completed | 448 | 12 | Supported | [74] |
| Brodalumab | IL-17RA | I | Completed | 40 | 48 | Not confirmed | [75] | II | Completed | 252 | 12 | Not confirmed | [76] |
|
|
n/a: no information available.
|